Efficacy of bevacizumab combined with TACE in the treatment of advanced hepatocellular carcinoma

Abstract

Abstract: Objective To evaluate the safety and efficacy of bevacizumab combined with transcatheter arterial chemoembolization (TACE) versus TACE monotherapy in the treatment of advanced hepatocellular carcinoma (HCC).Methods One hundred patients with advanced HCC admitted to our hospital from January 2018 to November 2019 were enrolled. They were divided into the combined group and the TACE group according to the treatment method. There were 50 cases in each group. The objective response rate (ORR) and tumor control rate (DCR) of 2 groups were compared. The levels of alpha fetoprotein (AFP) before and after treatment, the half-year survival rate, 18-month survival rate and median survival time between the 2 groups were compared.Results After 3 courses of treatment, enhanced magnetic resonance imaging (MRI) showed that the ORR of combination group and TACE group were 70.0% and 35.00% respectively, the difference was statistically significant (χ²=4.856, P=0.025); DCR of combination group and TACE group were 84.00% and 68.00% respectively, the difference was statistically significant (χ²=3.256, P=0.034). The AFP level of 2 groups decreased significantly after 3 courses of treatment, the AFP levels before and after treatment were significantly different in each group (P<0.05), and the AFP levels between the 2 groups were not significantly different (P>0.05). The half-year and 18-month survival rates of combined group were 90% and 50% respectively, which were significantly higher than those of TACE group, and the differences were statistically significant (χ²=4.726, P=0.032 and χ²=4.115, P=0.041, respectively). Kaplan-Meier analysis showed that the median survival time of patients in combined group and TACE group were 18 and 9 months, and the difference was statistically significant (χ²=7.012, P=0.007). The position of the survival curve of combination group was higher than that of TACE group, suggesting that the clinical efficacy of combined treatment was better.Conclusion The clinical efficacy of bevacizumab combined with TACE is better than TACE monotherapy in the treatment of advanced HCC, and the combined therapy can effectively improve the survival rate.

Key words: Hepatocellular carcinoma, Bevacizumab, Transcatheter arterial chemoembolization, Efficacy

LI Long, ZHENG Zhen-dong, DU Cheng, LIU Bo-na. Efficacy of bevacizumab combined with TACE in the treatment of advanced hepatocellular carcinoma[J]. Chinese Hepatolgy, 2022, 27(3): 281-283.

References

[1] 黄群国,刘启榆,周莹,等.肝动脉化疗栓塞术联合射频消融术治疗不可切除肝细胞癌的疗效分析.中西医结合肝病杂志,2020,30:502-505,515.
[2] 杨彦鸿, 曹碧辉, 陈德基. TACE联合索拉非尼或阿帕替尼治疗中晚期肝细胞癌. 中国介入影像与治疗学, 2019, 16:735-740.
[3] 胡捷,周俭.阿替利珠单抗联合贝伐珠单抗使肝癌治疗燃起希望.肝脏,2020,25:903-904.
[4] 李东玲, 周京旭, 朱茗祺,等. 西妥昔单抗和贝伐珠单抗治疗晚期结直肠癌的有效性和安全性比较. 现代生物医学进展, 2019, 19:1482-1485.
[5] 张琼,张晶,余智操,等. 肝细胞癌抗血管生成治疗药物的临床研究现状.临床肿瘤学杂志,2019,24:375-381.
[6] 杨锦锋,曾荣耀. 血管内皮生长因子和缺氧诱导因子-1α的表达与原发性肝癌患者临床病理特征及预后的关系. 中国慢性病预防与控制, 2020, 28:924-927.
[7] Le TBU, Vu TC, Ho RZW, et al. Bevacizumab augments the antitumor efficacy of infigratinib in hepatocellular carcinoma. INT J MOL SCI, 2020, 21:9405.
[8] 徐蕾,邢丽,李明,等.KRAS基因状态对晚期结直肠癌一线化疗联合贝伐珠单抗疗效的预测价值.蚌埠医学院学报,2019,44:593-596.
[9] 李月红, 徐蕾, 李明,等. 恶性胸膜间皮瘤给予贝伐珠单抗靶向治疗的研究进展. 临床肺科杂志, 2019, 24:556-558.
[10] 梁振雄, 王若天, 符敏,等. 贝伐珠单抗联合XELOX化疗对结直肠癌疗效,血清CRP水平及生存时间的影响. 实用癌症杂志, 2020, 35:326-329.
[11] 宋琳,韩芸,魏丽群, 等.贝伐珠单抗联合紫杉醇/卡铂方案对晚期非鳞非小细胞肺癌患者相关细胞生长因子及肿瘤标志物的影响.实用药物与临床,2020,23:510-513.
[12] 杜文龙,王佳,郭渊先,杨小萍,尹兰宁.贝伐珠单抗联合FOLFOX方案治疗进展期结直肠癌的临床疗效和安全性Meta分析.国际外科学杂志,2020,47:245-251,289-290.
[13] 柯华, 刘咏梅, 陈维永,等. 贝伐珠单抗联合化疗对肺腺癌患者恶性胸腔积液的疗效及安全性研究. 中国临床保健杂志, 2019, 22:484-487.

[1]	DING Xiao-peng, TIE Jun, YU Jia-hao, REN Peng-wei, XUAN Guo-yun, MA Shuo-yi, GUO Chang-cun, HAN Ying, ZHOU Xin-min. Efficacy and safety of TACE combined with anti-angiogenic drugs and PD-1 inhibitors in the treatment of intermediate/advanced HCC [J]. Chinese Hepatolgy, 2022, 27(3): 277-280.
[2]	CHANG Li-xian, LIU Chun-yun, XIE Pian. Relationship between Glypican-3 expression level and tumor biological behavior in hepatocellular carcinoma tissues [J]. Chinese Hepatolgy, 2022, 27(3): 284-287.
[3]	YANG Yi, XI Zi-han, ZHANG Lin-ying. The expression and clinical significance of AURKB and TP53 in hepatocellular carcinoma [J]. Chinese Hepatolgy, 2022, 27(2): 188-192.
[4]	FENG Quan-ye, GENG Cheng-jun, YIN Hui-kang. Application of T2WI sequence image TA in the differential diagnosis of nodules and small hepatocellular carcinoma under the background of liver cirrhosis [J]. Chinese Hepatolgy, 2022, 27(2): 193-195.
[5]	ZHANG Feng-xiao, BAI Xue-song, HU Jinghua. Prediction of post-hepatectomy liver failure for hepatocellular carcinoma by model for end-stage liver disease and standardized future liver remnant [J]. Chinese Hepatolgy, 2022, 27(2): 196-198.
[6]	HE Xiao-yan, ZHANG Qiang-nu, YANG Liu, WANG Gui-zhi. RNA-binding protein CSTF2 promotes the proliferation and migration of hepatocellular carcinoma cells by regulating MCM6 [J]. Chinese Hepatolgy, 2022, 27(2): 203-209.
[7]	JI Qin, SHEN Yu-chneg, SHAO Chun-yan. The value of PIVKA Ⅱ and serum AFP - L3 levels for evaluating the prognosis of primary liver cancer after TACE Therapy [J]. Chinese Hepatolgy, 2022, 27(2): 210-212.
[8]	WANG Jia-le, LI Cheng, LI Guang-ming. The mechanism of lncRNA TSIX inhibiting proliferation and invasion of hepatocellular carcinoma cell by targeting miR-548-a-3p [J]. Chinese Hepatolgy, 2022, 27(2): 213-217.
[9]	LI Jiao-jiao, SHI Dou-dou, HUANG Qi-chao, TAO Mei. Expression and clinical significance of ACSL1 in hepatocellular carcinoma [J]. Chinese Hepatolgy, 2022, 27(1): 81-85.
[10]	SUN Wen-wen, ZHANG Ling-yun. Expression and significance of folate metabolic pathway genes in hepatocellular carcinoma——A bioinformatics analysis [J]. Chinese Hepatolgy, 2021, 26(8): 851-856.
[11]	WANG Kai-le, JIN Xian-de, WANG Zhen, ZHANG Xin, ZHOU Jie. The value of multimodal imaging quantitative parameters in the differential diagnosis of small hepatocellular carcinoma and dysplastic nodules on the background of cirrhosis [J]. Chinese Hepatolgy, 2021, 26(8): 861-865.
[12]	LV Shao-dong, WEI Yong-peng, WANG Zhuo, YUAN Jian-yong, LU Jun-hua. MST1 and MST2 in Hippo signaling pathway were critical in stemness maintenance and self-renewal of hepatocellular carcinoma stem cells [J]. Chinese Hepatolgy, 2021, 26(8): 866-870.
[13]	YUAN Yi-ran, CHEN Long, ZHANG Zhen. miR-548a-5p regulates the apoptosis of hepatocellular carcinoma cell line HepG2 by targeting HMBOX1 [J]. Chinese Hepatolgy, 2021, 26(8): 871-873.
[14]	MAO Yan-qun, ZHOU Xue-shi, WANG Xia, SU Ting-ting, DU He-juan, GUO Xiao-ye, ZHOU Ling-xiao, QIU Yuan-wang. Study on the correlation between antithrombin III activity and short-term prognosis of acute-on-chronic liver failure patients treated with artificial liver support system [J]. Chinese Hepatolgy, 2021, 26(7): 770-775.
[15]	ZHANG Xiu-cui, LI Ming-long, HANG Xiao-feng, WEI Bo. The role of ulinastatin in the treatment of acute-on-chronic liver failure: a retrospective cohort study [J]. Chinese Hepatolgy, 2021, 26(7): 776-778.